NeuroQuest Featured in Israel21c

Blood Test for Alzheimer’s Begins Clinical Trials

Israeli biotech NeuroQuest set to start U.S. clinical trial of its simple test to diagnose the dreaded brain disorder in older individuals at risk.

NeuroQuest CEO Dan Touitou presents at a Trendlines Medical U.S. Road Show event in Atlanta, Georgia.

NeuroQuest CEO Dan Touitou presents at a Trendlines Medical U.S. Road Show event in Atlanta, Georgia.

NeuroQuest Development Center is working with the University of California-San Diego to collect and process blood samples for clinical validation trials of NeuroQuest’s blood test for early diagnosis of Alzheimer’s disease (AD).

Designed to be an inexpensive, convenient alternative to costly positron emission tomography (PET) brain scans, the NeuroQuest blood test can potentially identify a pre-clinical stage of AD years before the onset of noticeable symptoms.

The blood test is based on the principles of protective autoimmunity and nearly 20 years of award-winning research led by Prof. Michal Schwartz of the Weizmann Institute of Science in Rehovot, Israel, and president of the International Society of Neuroimmunology.

Worldwide, nearly 44 million people have Alzheimer’s or a related dementia. Yet there is no objective, accurate, cost-effective and practical tool for early diagnosis. Read the full article on Israel21c.

Leave a Reply

  • Welcome to Trendlines

    We invest in, incubate, and support early-stage, high-promise medical and agricultural technology companies in Israel, a global leader in start-up ingenuity. Read More >

  • Categories

  • Subscribe to Our Newsletter

  • Stay in Touch

    icon-facebook Like us on Facebook

    icon-Twitter Follow us on Twitter

    icon-Linkedin Connect with us on Linkedin

    YouTube-color See us on YouTube

    flipboard  Read us on Flipboard

    google+_icon Join us on Google+

Font Resize
Contrast